title: Endogenous fluorescence spectroscopy of cell suspensions for chemopreventive drug monitoring.
abstract: Cancer chemopreventive agents such as N-4-(hydroxyphenyl)retinamide (4HPR) are thought to prevent cancers by suppressing growth or inducing apoptosis in precancerous cells. Mechanisms by which these drugs affect cells are often not known, and the means to monitor their effects is not available. In this study endogenous fluorescence spectroscopy was used to measure metabolic changes in response to treatment with 4HPR in ovarian and bladder cancer cell lines. Fluorescence signals consistent with nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD) and tryptophan were measured to monitor cellular activity through redox status and protein content. Cells were treated with varying concentrations of 4HPR and measured in a stable environment with a sensitive fluorescence spectrometer. Results suggest that redox signal of all cells changed in a similar dose-dependant manner but started at different baseline levels. Redox signal changes depended primarily on changes consistent with NADH fluorescence, whereas the FAD fluorescence remained relatively constant. Similarly, tryptophan fluorescence decreased with increased drug treatment, suggesting a decrease in protein production. Given that each cell line has been shown to have a different apoptotic response to 4HPR, fluorescence redox values along with changes in tryptophan fluorescence may be a response as well as an endpoint marker for chemopreventive drugs.
authors.affiliation: Division of Biomedical Engineering, University of Arizona, Tucson, AZ, USA.
authors.forename: Nathaniel D
authors.initials: ND
authors.lastname: Kirkpatrick
authors.forename: Changping
authors.initials: C
authors.lastname: Zou
authors.forename: Molly A
authors.initials: MA
authors.lastname: Brewer
authors.forename: William R
authors.initials: WR
authors.lastname: Brands
authors.forename: Rebekah A
authors.initials: RA
authors.lastname: Drezek
authors.forename: Urs
authors.initials: U
authors.lastname: Utzinger
mesh_terms: D016588:Anticarcinogenic Agents / Q000378:metabolism*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D017313:Fenretinide / Q000378:metabolism*; D006801:Humans; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology; D013050:Spectrometry, Fluorescence / Q000379:methods*; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000473:pathology
chemical_list: D016588:Anticarcinogenic Agents; D017313:Fenretinide